Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study.

Dujovne, C A; Bays, H; Davidson, M H; Knopp, R; Hunninghake, D B; Stein, E A; Goldberg, A C; Jones, P; Lipka, L J; Cuffie-Jackson, C

Dujovne, C A; Bays, H; Davidson, M H; Knopp, R; Hunninghake, D B; Stein, E A; Goldberg, A C; Jones, P; Lipka, L J; Cuffie-Jackson, C.

Dujovne CA; Kansas Foundation for Clinical Pharmacology, Radiant Research Center-Kansas City, 12200 W. 106th, Suite 330, Overland Park, KS 66215, USA.

J Clin Pharmacol ; 41(1): 70-8, 2001 Jan.

Article en En | MEDLINE | ID: mdl-11144997

Asunto(s)

Anticolesterolemiantes/uso terapéutico; Azetidinas/uso terapéutico; LDL-Colesterol/sangre; Hipercolesterolemia/tratamiento farmacológico; Anticolesterolemiantes/efectos adversos; Apolipoproteína A-I/sangre; Azetidinas/efectos adversos; HDL-Colesterol/sangre; Relación Dosis-Respuesta a Droga; Método Doble Ciego; Femenino; Humanos; Hipercolesterolemia/sangre; Lovastatina/uso terapéutico; Masculino; Persona de Mediana Edad; Placebos; Triglicéridos/sangre

Search on Google

Imprimir

XML

PubMed Links

Banco de datos: MEDLINE Asunto principal: Azetidinas / Hipercolesterolemia / LDL-Colesterol / Anticolesterolemiantes Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2001 Tipo del documento: Article

Search on Google

Imprimir

XML

PubMed Links